RxDoctor Payments Data

Nalini Mattai, MD

General Practice · Pasadena, CANPI 1982803052

Payments from drug & device makers

$6,037in general payments, 2019–2025

Across 281 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$802
  • Novo Nordisk$707
  • AstraZeneca$488
  • GSK$470
  • Lilly USA, LLC$456
  • Sanofi Pasteur Inc.$434
  • plus $3K from 22 others

What the payments were for

  • Food & beverage$6,026100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,037 in reported general payments places this provider in the 95th percentile of 12,963 general practice providers in California.

See all general practice providers in California

Medicare billing

Part B allowed, 2024
$186,625
Medicare patients
327
Services billed
2,620

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin37$61,164
TrulicityDulaglutide35$46,128
OzempicSemaglutide31$38,631
MounjaroTirzepatide35$36,219
Wellbutrin XlBupropion Hcl13$33,530
XareltoRivaroxaban25$30,543
Repatha SureclickEvolocumab22$21,955
EliquisApixaban32$19,683
JanuviaSitagliptin Phosphate12$16,954
FarxigaDapagliflozin Propanediol20$16,937
Memantine Hcl ErMemantine Hcl26$4,794
Rosuvastatin Calcium225$4,118
Atorvastatin Calcium238$2,741
Wixela InhubFluticasone Propion/Salmeterol21$2,632
Levothyroxine Sodium190$2,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$456$82,34770 claims
Boehringer IngelheimJardiance$157$61,16437 claims
Novo NordiskOzempic$707$38,63131 claims
PfizerEliquis, Paxlovid$149$21,11246 claims
MerckJanuvia$237$16,95412 claims
AstraZenecaFarxiga$488$16,93720 claims
AbbVieSynthroid$802$1,77723 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 12,963 general practice providers in California.

Other general practice in Pasadena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →